87647025
Oct 16, 2017
Medicines for the treatment of refractory epilepsy, epilepsy, autism, anxiety including cannabinoids and/or cannabidiol (CBD), with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis
PharmaceuticalsPharmaceutical research and development for medicines including cannabinoids and/or cannabidiol (CBD), with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, for the treatment of refractory epilepsy, epilepsy, autism and anxiety; scientific and medical research in the field of cannabinoids and/or cannabidiol (CBD) contained medicines, with a delta-9 tetrahydrocannabinol (THC) concentration of not more than 0.3 percent on a dry weight basis, for the treatment of refractory epilepsy, epilepsy, autism and anxiety
Computer and Scientific